Association studies of genetic variants and obesity and/or obesity-related risk
factors have yielded contradictory results. The aim of the present study was to
determine the possible association of five single-nucleotide polymorphisms (SNPs)
located in the IGF2, LEPR, POMC,
PPARG, and PPARGC1genes with obesity or
obesity-related risk phenotypes. This case-control study assessed overweight (n=192)
and normal-weight (n=211) children and adolescents. The SNPs were analyzed using
minisequencing assays, and variables and genotype distributions between the groups
were compared using one-way analysis of variance and Pearson's chi-square or Fisher's
exact tests. Logistic regression analysis adjusted for age and gender was used to
calculate the odds ratios (ORs) for selected phenotype risks in each group. No
difference in SNP distribution was observed between groups. In children, POMC
rs28932472(C) was associated with lower diastolic blood
pressure (P=0.001), higher low-density lipoprotein (LDL) cholesterol (P=0.014), and
higher risk in overweight children of altered total cholesterol (OR=7.35, P=0.006).
In adolescents, IGF2 rs680(A) was associated with
higher glucose (P=0.012) and higher risk in overweight adolescents for altered
insulin (OR=10.08, P=0.005) and homeostasis model of insulin resistance (HOMA-IR)
(OR=6.34, P=0.010). PPARG rs1801282(G) conferred a
higher risk of altered insulin (OR=12.31, P=0.003), and HOMA-IR (OR=7.47, P=0.005) in
overweight adolescents. PARGC1 rs8192678(A) was
associated with higher triacylglycerols (P=0.005), and LEPR
rs1137101(A) was marginally associated with higher LDL
cholesterol (P=0.017). LEPR rs1137101(A) conferred
higher risk for altered insulin, and HOMA-IR in overweight adolescents. The
associations observed in this population suggested increased risk for cardiovascular
diseases and/or type 2 diabetes later in life for individuals carrying these
alleles.
ABSTRACT. Ancestry-informative markers (AIMs) are powerful tools for inferring the genetic composition of admixed populations. In this study, we determined the genetic ancestry of the Ouro Preto (Brazil) population and evaluated the association between ancestry and self-reported skin color. The genetic ancestry of 189 children Genetic composition of a Brazilian population and adolescents was estimated by genotyping 15 AIMs. The estimate of population admixture was determined using the Bayesian Markov Chain Monte Carlo (MCMC) method implemented in two different programs (STRUCTURE and ADMIXMAP). Volunteers self-reported their skin colors. The European ancestry contribution ranged from 0.503 to 0.539, the African contribution ranged from 0.333 to 0.425, and the Amerindian component ranged from 0.04 to 0.164. The relative contributions of African (P < 0.016) and European (P < 0.011) ancestry differed significantly among skin color groups, except between black and dark-brown groups. The population of Ouro Preto has a higher contribution of African ancestry compared to the mean for the southeast region of Brazil. Therefore, extrapolating the African ancestry contribution for southeastern Brazil to the Ouro Preto population would underestimate the actual value for this city. We also showed that selfreported skin color could be appropriate for describing the genetic structure of this particular population.
Background: Studies in admixed populations show that the prevalence of obesity and related diseases, such as type 2 diabetes and hypertension, may vary by ethnic group. The aim of this study was to investigate the relationship of genetic ancestry with phenotypes associated with obesity in a sample of school children and adolescents from Ouro Preto, Minas Gerais.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.